STOCK TITAN

Athira Pharma, Inc. - ATHA STOCK NEWS

Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.

Overview

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative small molecule therapeutics designed to restore neuronal health and slow the progression of neurodegenerative diseases. Utilizing proprietary and patented technologies to modulate the neurotrophic hepatocyte growth factor (HGF) system, Athira Pharma addresses the underlying mechanisms of neurological degeneration by promoting neuroprotection, neurotrophic support, and anti-inflammatory activity. Focused on conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other debilitating neurodegenerative disorders, the company brings a differentiated approach to an industry traditionally dominated by symptomatic treatments.

Core Scientific Approach

The company’s strategy centers on the positive modulation of the endogenous HGF system, which is critical for neuronal repair and survival. By harnessing this pathway, Athira develops candidates that may not only halt the progression of neurodegeneration but also potentially reverse some of the neuronal damage. Their approach underlines several key scientific principles:

  • Neuroprotection: Safeguarding neurons against toxins and pathological processes.
  • Neurotrophic Enhancement: Stimulating repair and recovery mechanisms within the central nervous system.
  • Anti-inflammatory Action: Reducing neuroinflammation which is a prominent feature in many neurodegenerative diseases.
This multi-pronged approach distinguishes Athira’s work from many companies that focus solely on symptom alleviation and offers an opportunity for transformative therapies in neurology.

Pipeline and Therapeutic Candidates

Athira Pharma has advanced several promising candidates in its pipeline. Among these, fosgonimeton (ATH-1017) is a potentially first-in-class therapeutic designed for once daily subcutaneous administration. Fosgonimeton is engineered to enhance the activity of the HGF system, thereby activating neuroprotective and neurotrophic pathways to counteract pathogenic processes associated with Alzheimer’s disease and other neurodegenerative conditions.

The company is also developing ATH-1020 and ATH-1105, both of which are next-generation, orally administered small molecule therapeutics. ATH-1020 is envisioned to further refine the modulatory effects on the HGF system, while ATH-1105 is being evaluated as a candidate for treating amyotrophic lateral sclerosis (ALS), based on its potential to improve motor and nerve function, extend neuronal survival, and reduce biomarkers indicative of neurodegeneration.

Market Position and Competitive Differentiation

Athira Pharma occupies a unique niche at the intersection of neurodegenerative research and small molecule drug development. The company’s focus on modulating the neurotrophic HGF system provides a robust foundation for addressing the underlying pathology of neurodegenerative diseases, rather than merely managing symptoms. In a competitive landscape where many organizations concentrate on either biologics or novel antibody treatments, Athira’s emphasis on small molecule candidates offers several advantages, including ease of administration, potential for oral delivery, and a tailored mechanism of action that leverages endogenous repair pathways.

Additionally, Athira’s clinical-stage status, bolstered by extensive preclinical data and multiple clinical trial presentations at major industry conferences, attests to its rigorous research and development processes. This reinforces the company’s commitment to advancing therapeutic candidates with a strong emphasis on safety, tolerability, and mechanistic validation.

Scientific Rigor and Research Developments

The company’s research is characterized by a methodical exploration of neurodegenerative mechanisms. Detailed preclinical studies have showcased the ability of fosgonimeton to counteract key pathological mechanisms such as amyloid-beta toxicity, tau hyperphosphorylation, mitochondrial dysfunction, and neuroinflammation. Such comprehensive data sets underscore the potential of targeting the HGF pathway to yield clinical benefits that surpass the effects observed in current treatment paradigms.

Beyond target validation, Athira’s adoption of robust biomarkers—such as plasma neurofilament light chain (NfL) and phosphorylated tau (pTau)—further demonstrates their commitment to a data-driven approach. These biomarkers provide crucial insights during clinical assessments and have been used consistently across trials to measure the impact of their therapeutic candidates on neurodegenerative processes.

Operational Focus and Corporate Strategy

Headquartered in the Seattle, Washington area, Athira Pharma leverages its base in a region renowned for advancements in biomedical research and innovation. The company employs rigorous clinical trial methodologies and has engaged with prominent research institutions, which enhances its capacity to design, conduct, and interpret clinical studies. Its strategic focus on the HGF system, combined with a thoughtful portfolio of small molecule therapeutics, positions Athira to address critical unmet needs in neurodegenerative disease treatment.

Athira also emphasizes transparency in its research and clinical developments. By sharing clinical data and participating in leading industry conferences, the company demonstrates its commitment to advancing scientific understanding and fostering collaborative validation of its therapeutic approaches.

Investor and Industry Relevance

The comprehensive development pipeline and the focus on disease-modifying therapies make Athira Pharma a company of interest for those researching investment opportunities in biopharmaceutical innovation. The company’s detailed attention to mechanistic understanding and biomarker validation provides transparency for evaluating the scientific rationale behind its clinical programs. Its portfolio not only aims to deliver symptomatic relief but also to impact the underlying disease processes, offering a potential shift in how neurodegenerative diseases are treated.

In summary, Athira Pharma, Inc. embodies a cutting-edge approach to neurodegeneration by leveraging small molecule drug candidates that modulate the HGF system. The company’s extensive research, diversified pipeline, and focus on critical biomarkers establish it as a thought leader in its field, positioned firmly within the competitive biopharmaceutical landscape while maintaining an unwavering commitment to enhancing neuronal health and function.

Conclusion

Athira Pharma’s work epitomizes the integration of advanced scientific research with focused clinical development. Through its pursuit to restore neuronal health and mitigate neurodegeneration, it offers significant insights and potential advancements in the treatment of complex neurological disorders. As the company continues to generate robust clinical and preclinical data, it remains a pivotal organization for those seeking to understand the future of disease-modifying therapies in neurodegenerative research.

Rhea-AI Summary

Athira Pharma has placed Leen Kawas on temporary leave pending a review related to her doctoral research at Washington State University. Mark Litton, currently COO, will take over leadership responsibilities. An independent committee has been formed for the review. Despite this, the company remains confident in its lead drug ATH-1017, which has shown promising results in clinical trials for improving cognitive functions and addressing neurodegenerative diseases. Athira emphasizes its commitment to scientific integrity amidst this review process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.87%
Tags
none
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) appointed Rachel Lenington as Chief Technology Officer, effective June 14, 2021. Lenington brings over 20 years of experience from organizations like Seagen Inc and the Bill & Melinda Gates Foundation. Her expertise in R&D, drug development, and commercialization is expected to bolster Athira's efforts in neurodegenerative disease treatments. CEO Leen Kawas expressed optimism about her leadership enhancing the company's product strategies. Athira focuses on developing small molecules to restore neuronal health, notably its lead candidate, ATH-1017, targeting Alzheimer’s and Parkinson’s dementia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
management
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced its participation in two upcoming investor conferences: the JMP Securities Life Sciences Conference on June 17, 2021, at 3:30 PM ET and the Raymond James Human Health Innovation Conference on June 21, 2021, at 1:20 PM ET. Management will engage in discussions about neurodegenerative diseases, focusing on new therapeutic targets for conditions like Alzheimer’s and Parkinson’s. Webcasts of the presentations will be available on the company’s website for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
Rhea-AI Summary

Athira Pharma, Inc. (NASDAQ: ATHA) has appointed Mark Worthington as General Counsel, effective June 1, 2021. Worthington brings extensive legal experience from 24 years at Summit Law Group, particularly in corporate finance and governance. His role is expected to bolster Athira’s strategic business growth, as cited by CEO Leen Kawas. Athira is focused on developing therapies aimed at neurodegenerative disorders, with its lead candidate, ATH-1017, targeting Alzheimer’s and Parkinson’s disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
management
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. CEO Leen Kawas will engage in a fireside chat and one-on-one investor meetings during these events. Details include the fireside chat at the Jefferies Conference at 4:30 PM ET and the Goldman Sachs Conference at 5:30 PM ET. Webcasts for both events are available on the Athira website, with archived replays accessible for at least 30 days following each event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences
-
Rhea-AI Summary

Athira Pharma, Inc. (NASDAQ: ATHA) reported financial results for Q1 2021, highlighting a net loss of $8.9 million, or $0.25 per share. The company's cash position improved to $357.7 million following a successful follow-on public offering, raising $103.5 million. Athira is advancing its clinical trials for ATH-1017 in treating Alzheimer’s and Parkinson’s disease dementia, with Phase 2 trials expected to start by late 2021. The company remains focused on developing small molecules aimed at neurodegeneration, maintaining a clear strategic plan and ample funding for future milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company, announced that CEO Leen Kawas, Ph.D., will participate in the Sachs 4th Annual Neuroscience Innovation Forum on April 28, 2021, at 8:30 a.m. PT. The panel titled “Progress in Alzheimer’s and Dementia” will focus on advancements in treating neurodegenerative diseases. The event will also feature notable experts from AZTherapies, NIH, Johnson & Johnson Innovation, and more. A recording will be available starting May 26, and further details can be found on Athira's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
conferences
-
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) is hosting a webinar on April 15, 2021, at 1:30 p.m. PT to discuss its therapeutic approach targeting the HGF/MET pathway for neurodegeneration. Led by neurologist Marwan Sabbagh, M.D., the session will cover Alzheimer’s and dementia treatment landscapes and the role of hepatocyte growth factor in brain health. Kevin Church, Ph.D., will provide insights on Athira's lead candidate, ATH-1017, designed to enhance HGF/MET activity. Registration is available on Athira’s investor website, and a replay will be accessible for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
conferences
-
Rhea-AI Summary

Athira Pharma reported significant developments in its clinical trials and financial status as of March 25, 2021. The company is actively enrolling patients in LIFT-AD and ACT-AD studies for its investigational drug ATH-1017, aimed at treating Alzheimer’s disease. Notably, Athira raised $103.5 million in a follow-on public offering. Financially, the net loss for 2020 was $19.9 million, with cash reserves of $268.2 million expected to sustain operations through at least 2022. The firm anticipates IND submissions for Parkinson’s disease dementia and neuropsychiatric programs by the end of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA), a biopharmaceutical company focused on neuronal health, announced that its CEO, Leen Kawas, will participate in a virtual fireside chat at Stifel’s 3rd Annual CNS Conference on April 1, 2021, at 9:00 am ET. The event will be accessible via a live webcast on Athira's investor relations website, with an archived replay available for 90 days post-event. Athira is advancing its lead candidate, ATH-1017, targeting Alzheimer's and Parkinson's dementia, aiming to alter the course of neurological diseases and enhance cognitive abilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
conferences

FAQ

What is the current stock price of Athira Pharma (ATHA)?

The current stock price of Athira Pharma (ATHA) is $0.25 as of April 4, 2025.

What is the market cap of Athira Pharma (ATHA)?

The market cap of Athira Pharma (ATHA) is approximately 10.0M.

What is the primary focus of Athira Pharma, Inc.?

Athira Pharma is focused on developing small molecule therapeutics that restore neuronal health and slow neurodegeneration by modulating the neurotrophic HGF system.

What are the key therapeutic areas that Athira Pharma targets?

The company targets a range of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS, and other related neurological disorders.

How does Athira Pharma’s approach differ from other neurodegenerative treatments?

Unlike many treatments that address only the symptoms, Athira Pharma’s approach targets the underlying disease mechanisms by activating neuroprotective, neurotrophic, and anti-inflammatory pathways.

What are the main drug candidates in Athira Pharma’s pipeline?

Athira’s pipeline includes fosgonimeton (ATH-1017), a potentially first-in-class candidate, and next-generation oral candidates such as ATH-1020 and ATH-1105, each designed to modulate the HGF system.

What role does the HGF system play in Athira Pharma’s therapeutic strategy?

The HGF system is critical for neuronal repair and survival. Athira Pharma’s candidates enhance this system to promote neuroprotection, improve neuron function, and potentially slow the progression of neurodegenerative diseases.

How does Athira Pharma validate the efficacy of its drug candidates?

The efficacy is assessed through comprehensive preclinical studies and clinical trials that include robust biomarker evaluations such as plasma neurofilament light chain (NfL) and phosphorylated tau measurements.

Where is Athira Pharma headquartered and how does its location benefit its operations?

Headquartered in the Seattle, Washington area, Athira benefits from a strong biomedical research environment and access to innovative research institutions, which supports its clinical and scientific development efforts.

What impact does Athira Pharma aim to have on the treatment of neurodegenerative diseases?

Athira aims to shift the treatment paradigm by not only alleviating symptoms but also addressing the underlying neurodegenerative processes, thereby potentially altering disease progression and improving patient outcomes.
Athira Pharma, Inc.

Nasdaq:ATHA

ATHA Rankings

ATHA Stock Data

9.99M
32.16M
2.9%
51.72%
2.27%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOTHELL